| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/29/2007 | US7223734 Comprises peptide which binds to fibrinogen and serves as a modulator of enzyme activity; for increasing the half- life of proteins and pro-drugs in circulation; for treatment of arteriosclerosis and emphysema |
| 05/29/2007 | US7223733 Modulation of TRIP-Br function and method of treating proliferative disorders |
| 05/29/2007 | US7223732 Polypeptides; wound healing agents, antiulcer agents |
| 05/29/2007 | US7223731 Comprises use of thrombospondin biological fragments and domains to treat and prevent cell proliferation disorders; antitumor agents |
| 05/29/2007 | US7223730 Antithrombosis enzyme from the snake venom of agkistrodon acutus |
| 05/29/2007 | US7223729 Suppressing an immune response, CD200, a molecule with previously unknown function belonging to the Ig superfamily, is an immune suppressant; preventing graft rejection, fetal loss, autoimmune diseases, allergies |
| 05/29/2007 | US7223728 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes |
| 05/29/2007 | US7223727 GSSP4 polynucleotides and polypeptides and uses thereof |
| 05/29/2007 | US7223726 Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| 05/29/2007 | US7223725 Exendin agonist compounds |
| 05/29/2007 | US7223724 Administering a polypeptide attached to a water soluble polymer; treating age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemlc retinopathies, retinal detachment and traumatic retinopathy |
| 05/29/2007 | US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 05/29/2007 | US7223593 Anticancer agents; gene coding immunomoderator cytokine protein |
| 05/29/2007 | US7223583 Antithrombotic thrombin variants |
| 05/29/2007 | US7223577 Post-translational modifications and Clostridial neurotoxins |
| 05/29/2007 | US7223563 Nucleic acids; diagnosing and treating hypophosphatemic disorders; diagnosing tumor induced osteomalacia |
| 05/29/2007 | US7223558 Fibronectins; drug screening; treating cardiovascular/nervous system disorders |
| 05/29/2007 | US7223554 Inhibitors of proteasomal activity for stimulating hair growth |
| 05/29/2007 | US7223548 Cotransfecting cells with nucleic acid; dividing into portions to be drug screened and unscreened for regulators of expression of human aromatase gene; determining level of gene expression of reporter gene; breast cancer |
| 05/29/2007 | US7223547 for drug screening using genomic expression libraries; solid phase synthesis; kits; genetic engineering |
| 05/29/2007 | US7223542 Diagnosing cancer via determining concentration of marker polypeptides; genetic vaccines; antiproliferative/antitumor agents |
| 05/29/2007 | US7223535 Using epitopic amino acid sequences to detect/diagnose hepatitis A viral infection; immunoassay |
| 05/29/2007 | US7223440 Residual solvent extraction method and microparticles produced thereby |
| 05/29/2007 | US7223408 Human papillomavirus E6 and E7 polypeptides, mutant polypeptide retains 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7 |
| 05/29/2007 | US7223406 Administering one or more factors selecting from vascular endothelial growth factor, brain-derived neurotrophic factor, fibroblast growth factor, neurotrophins or angiopoietin-1; promoting the growth of new nerve fibers; tissue engineering |
| 05/29/2007 | US7223399 administering the toxin directly to a blood vessel, especially following a cardiovascular procedure. |
| 05/29/2007 | US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target |
| 05/29/2007 | US7223396 Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies |
| 05/29/2007 | US7223394 Human antibodies that bind human TNFα |
| 05/29/2007 | US7223392 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| 05/29/2007 | US7223389 Compositions and methods for treatment of cancer |
| 05/29/2007 | US7223386 comprising silicone matrix, a hydrophilic carrier, and at least one active agent comprising proteins, particularly enzymes such as hydrolases and glucose oxidase for enzymatic debridement, clotting formation and clot removal and wound healing |
| 05/29/2007 | CA2341685C Secreted renilla luciferase |
| 05/29/2007 | CA2274853C Multiple branch peptide constructions |
| 05/29/2007 | CA2268758C Immunogenic detoxified mutant e. coli lt-a toxin |
| 05/29/2007 | CA2251297C Oral preparations comprising s-(3-hydroxypropyl)-l-cysteine |
| 05/29/2007 | CA2236998C Tissue-specific and target rna-specific ribozymes |
| 05/29/2007 | CA2214565C New cryptophycins from synthesis |
| 05/28/2007 | CA2569326A1 Compositions and methods to create a vascularized environment for cellular transplantation |
| 05/24/2007 | WO2007059491A2 Novel hydrogels and uses thereof |
| 05/24/2007 | WO2007059357A1 Methods of regulating renalase (monoamine oxidase c) |
| 05/24/2007 | WO2007059342A2 Random copolymer compositions for treating unwanted immune response |
| 05/24/2007 | WO2007059211A2 Methods of treating fibrosing diseases by induction of immune tolerance |
| 05/24/2007 | WO2007059190A2 Compositions of and methods of using stabilized psma dimers |
| 05/24/2007 | WO2007059031A2 Methods and compositions for raising levels and release of gamma aminobutyric acid |
| 05/24/2007 | WO2007058982A2 Mntf differentiation and growth of stem cells |
| 05/24/2007 | WO2007058970A2 RECEPTOR ANTAGONIST AS THERAPEUTIC AGENTS FOR iNOS GENERATING ILLNESS |
| 05/24/2007 | WO2007058902A1 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin |
| 05/24/2007 | WO2007058879A2 Inhibitors of akt activity |
| 05/24/2007 | WO2007058878A2 Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1) |
| 05/24/2007 | WO2007058800A2 Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
| 05/24/2007 | WO2007058776A2 Hepatocyte growth factor intron fusion proteins |
| 05/24/2007 | WO2007058678A2 Uses of pegylated albumin |
| 05/24/2007 | WO2007058634A1 Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension |
| 05/24/2007 | WO2007058625A1 Toxin-antitoxin system and applications thereof |
| 05/24/2007 | WO2007058612A1 Medicament for use in connection with cartilage impairment |
| 05/24/2007 | WO2007058536A1 Pharmaceutical composition for treating or preventing ovarian cancer |
| 05/24/2007 | WO2007058392A1 Heterocyclic compound and medicinal application thereof |
| 05/24/2007 | WO2007058383A2 Lipid secretion promoter containing lacritin or compound having lacritin activity |
| 05/24/2007 | WO2007058381A1 Novel highly functional enzyme having modified substrate-specificity |
| 05/24/2007 | WO2007058360A1 Therapeutic agent for skin or skin repair-promoting agent comprising des-acylghrelin or derivative thereof as active ingredient |
| 05/24/2007 | WO2007058359A1 THERAPEUTIC AGENT FOR SKIN OR SKIN REPAIR-PROMOTING AGENT COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT |
| 05/24/2007 | WO2007057922A1 Targeted fusion proteins for cancer therapy |
| 05/24/2007 | WO2007057749A2 Agent for use in the case of fructose intolerance |
| 05/24/2007 | WO2007057670A1 Nidogen/snep-iike molecule |
| 05/24/2007 | WO2007057648A1 Inhibitors of bcl-6 |
| 05/24/2007 | WO2007057617A1 Lectin-defencin chimeric protein |
| 05/24/2007 | WO2007057444A1 Insl3/rlf polypeptides and uses thereof |
| 05/24/2007 | WO2007057436A2 Interferon in influenza |
| 05/24/2007 | WO2007057431A1 New method for treating cancer based on the modulation of calcineurin |
| 05/24/2007 | WO2007057212A1 High activity growth factor mutants |
| 05/24/2007 | WO2007057005A1 Lipopeptide compositions |
| 05/24/2007 | WO2007056907A1 TRUNCATED GLUCAGON-LIKE PEPTIDE-1 (sGLP-1) AND ITS PREPARING METHOD AND USE |
| 05/24/2007 | WO2007056867A1 Modified pore-forming protein toxins and use thereof |
| 05/24/2007 | WO2007056852A1 Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| 05/24/2007 | WO2007056812A1 A molecule and chimeric molecules thereof |
| 05/24/2007 | WO2007056811A1 Zingiber plant extract |
| 05/24/2007 | WO2007047430A3 Method of treating acute failure with thrombomodulin variant |
| 05/24/2007 | WO2007041206A3 Drug delivery nanocarriers targeted by landscape phage |
| 05/24/2007 | WO2007040591A9 A ubiquinone composition and a container for its convenient transport and storage |
| 05/24/2007 | WO2007038933A3 A method for producing cells with efficient engraftment within the heart |
| 05/24/2007 | WO2007038683A3 Calcium binding peptides |
| 05/24/2007 | WO2007027574A3 Cyclic peptide isolation by spray drying |
| 05/24/2007 | WO2007020195A3 Peg-ifn alpha and ribavirin for hbv treatment |
| 05/24/2007 | WO2007019453A3 Treatment of wounds using il-17b |
| 05/24/2007 | WO2007017914A3 Dermonecrotizing protein factors of bacterial origin and related uses in medical field |
| 05/24/2007 | WO2007016593A3 Antifungal peptides and methods of use thereof |
| 05/24/2007 | WO2007016018A3 Improved botulinum toxin compositions |
| 05/24/2007 | WO2007014199A3 Tfpi fragments as anti-microbial agents |
| 05/24/2007 | WO2006135506A3 Compositions for topical enzymatic debridement |
| 05/24/2007 | WO2006133089A3 Improved human interferon molecules and their uses |
| 05/24/2007 | WO2006122327A8 Milk fat globule epidermal growth factor-factor viii and sepsis |
| 05/24/2007 | WO2006116302A3 High-potency botulinum toxin formulations |
| 05/24/2007 | WO2006102611A3 Therapeutic agents for the treatment of leukemia |
| 05/24/2007 | WO2006095347A3 VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS |
| 05/24/2007 | WO2006087550A3 Amyloid-binding peptides, analogues and uses thereof |
| 05/24/2007 | WO2006077232A3 Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation |
| 05/24/2007 | WO2006045796A9 Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
| 05/24/2007 | WO2006042408A9 Gh secretagogues and uses thereof |
| 05/24/2007 | WO2006035431A3 Fatty acid modified polylysines as antimicrobial agents |